LONGEVA.

PT-141 (bremelanotide): adverse events and evidence limits

During the 24-week core trials of subcutaneous bremelanotide in premenopausal women with HSDD, nausea, flushing and headache were more common than with placebo. [1]

Investigators also described drug-related vomiting/headache requiring hospitalization. This does not establish catalog-reagent risks. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
NauseaPremenopausal women with HSDD, subcutaneous bremelanotide, 24-week core trial phaseMore common than with placebo; no percentage given in the abstract[1]
FlushingThe same participantsMore common than with placebo; no frequency given[1]
HeadacheThe same participantsMore common than with placebo; no frequency given[1]
Vomiting/headache requiring hospitalizationThe same participantsDescribed by investigators as drug-related[1]

References

  1. Sheryl A Kingsberg et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. 10.1097/AOG.0000000000003500.